Pharma's Big Rebate Spenders

Source: Company 10-K filings and annual reports compiled by "The Pink Sheet"; *refers to filings where rebates are recorded as running balances with accruals and payments, with the reported figure being the amount of payments by the pharma company in 2015. (1) Chargebacks are reimbursements to wholesalers which honor contracted prices to third parties and can be hefty.

This story has also been published in "The Pink Sheet". Scrip Intelligence brings selected complementary coverage from our sister publications to our subscribers.

Drug Manufacturer	2015 Net Revenues	2015 Rebate Spending
Novartis	$49.41bn	$1.42bn US specific health care plans and program rebates for pharmaceuticals*
Pfizer	$48.9bn	$2.25bn on contract rebates with managed care customers bin the US; $2.24bn on Medicare/Medicaid
Sanofi	€34.54bn ($39.91bn)	€1.64bn ($1.85bn) managed care and GPO programs, mainly rebates and other price reductions grated to healthcare authorities in the US; €4.3bn ($4.84bn) mainly US Medicare/Medicaid*
Johnson & Johnson	$31.4bn (pharmaceutical sales)	$9.72bn in rebate payments (pharma segment)*
GlaxoSmithKline	£23.92bn ($33.88bn)	£1.74bn ($2.46bn) in US market-driven programs; £1.87bn ($2.65bn) in government and state programs
Gilead	$32.64bn	$11.6bn in payments for government and other rebates and chargebacks for activities related to 2015 sales*(1)
AstraZeneca	$24.71bn	$7.54bn US contractual rebates (managed care and GPO); $1.71bn (US government and state programs)
Amgen	$21.66bn	$2.74bn payments in rebates*
AbbVie	$22.86bn	$1.77bn payments for managed care rebates; $1.4bn in Medicare/Medicaid rebate payments
Eli Lilly & Co.	$19.96bn	$5.93bn payments in rebates and sales discounts*
Allergan	$15.07bn	$4.04bn payments in rebates*
Total		$64.16bn

Industry's Rebate Arms Race: Securing Market Access At A Cost

More from Alimentary/Metabolic

More from Therapeutic Category